Bone Biologics Corp

For the period ended Mar 31, 2026. Filed May 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Balance Sheets

Condensed Consolidated Balance Sheets

	March 31, 2026	December 31, 2025
(unaudited)
Assets
Current Assets
Cash	$4,530,040	$5,334,322
Advances on research and development contract services	208,972	208,972
Prepaid insurance	170,527	232,946
Prepaid financing costs	51,957
Interest Receivable	7,809	9,895
Prepaid expenses	10,000	10,000
Total current assets	4,979,305	5,796,135
Total assets	$4,979,305	$5,796,135
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued expenses	$308,948	$417,884
Warrant liability	438	703
Total current liabilities	309,386	418,587
Total liabilities	309,386	418,587
Commitments and Contingencies	-	-
Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at March 31, 2026 and December 31, 2025	-	-
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,795,260 shares issued and outstanding at March 31, 2026 and December 31, 2025	1,795	1,795
Additional paid-in capital	93,564,481	93,506,122
Accumulated deficit	(88,896,357)	(88,130,369)
Total stockholders’ equity	4,669,919	5,377,548
Total liabilities and stockholders’ equity	$4,979,305	$5,796,135

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.